Feedback
Settings

Settings

Goto Application

1,357 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 136
1.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO - 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
 Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
2.20240299401NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER
US - 12.09.2024
Int.Class A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
 Appl.No 18030390 Applicant THE PENN STATE RESEARCH FOUNDATION Inventor Sougat MISRA

Disclosed herein are compositions and methods for increasing the expression of human SLC7A11. The compositions include a combination of compounds that exhibit anti-proliferative activity against cancer cells. The compositions and methods can be used to treat a subject with cancer. Disclosed are also compositions and methods of treating a coronavirus infection, Zika virus, influenza virus infection, human immunodeficiency virus (HIV), or Rhinovirus.

3.WO/2023/215763USE OF ZINC PORPHYRIN AS AN ANTIMICROBIAL
WO - 09.11.2023
Int.Class A61K 31/409
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
409having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
 Appl.No PCT/US2023/066516 Applicant ROBINSON, Jayne Inventor ROBINSON, Jayne
The present disclosure provides for a method of inhibiting the growth of a microorganism including contacting the microorganism with zinc porphyrin (ZnPor). The present disclosure also provides for a method of treating or preventing biofilm formation of one or more microorganisms including contacting the biofilm with zinc porphyrin (ZnPor). Further, the present disclosure provides for a method of treating a disease associated with biofilm formation in a subject including administering to the subject a composition comprising a therapeutically effective amount of ZnPor.
4.WO/2023/073086IRON OXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO - 04.05.2023
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/EP2022/080053 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless a new infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019 2021 coronavirus pandemic. The present invention discloses the use of coated iron oxide nanoparticles (IONPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV, SARS-CoV-2 and MERS-CoV. The iron oxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen, nitrogen and sulfur donor atoms (e.g. dextran, (3- aminopropyl)triethoxysilane or dimercaptosuccinic acid, respectively). The IONPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication, transcription and production of infectious virus. Furthermore, the IONPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
5.WO/2023/073091IRON OXYHYDROXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO - 04.05.2023
Int.Class A61K 33/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
26Iron; Compounds thereof
 Appl.No PCT/EP2022/080059 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless, a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019-2021 coronavirus pandemic. The present invention discloses the use of coated iron oxyhydroxide nanoparticles (lOHNPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV and SARS-CoV-2 and MERS-CoV. The iron oxyhydroxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen (e.g. sorbitol and sucrose). The lOHNPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication and transcription. Furthermore, the lOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
6.WO/2022/126127IODINE DELIVERY COMPOUNDS
WO - 16.06.2022
Int.Class A61K 33/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
18Iodine; Compounds thereof
 Appl.No PCT/US2021/072845 Applicant IOCURE, INC. Inventor FARB, Mark Daniel
Disclosed herein are methods and compositions for manufacturing pharmaceutical compositions and treating and ameliorating pathological conditions, using carriers conjugated to iodine-containing compounds; and therapeutic mixtures including iodine-containing compounds
7.WO/2021/181372AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF ACIDOSIS
WO - 16.09.2021
Int.Class A61K 33/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof
10Carbonates; Bicarbonates
 Appl.No PCT/IL2021/050103 Applicant AMORPHICAL LTD. Inventor BEN, Yossi
The preset invention is directed to ACC particles stabilized by at least one stabilizing agent, a pharmaceutical composition including same, and methods of using same, such as for treating or preventing an acidosis-related disease or condition in a subject in need thereof.
8.WO/2023/141673IMMUNOMODULATORY COMBINATION COMPRISING PLANT AND ANIMAL EXTRACTS HAVING ANTIVIRAL ACTIVITY
WO - 03.08.2023
Int.Class A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
 Appl.No PCT/AU2023/050043 Applicant PT AGRAPANA DAMAYANTI INDOBIOTEK Inventor MARCAL, Helder
The present invention relates to an immunomodulatory composition comprising a combination of agents consisting of a curcuminoid, an emodin, bioavailable zinc and an at least one active agent obtained from Tinospora cordifolia, as well as a composition comprising a combination of agents consisting of a Tinospora cordifolia extract, a Curcuma xanthorrhiza extract, an aloe extract and a moringa extract. Said composition may further comprising an agent selected from an albumin, a glutathione, ascorbic acid and bioavailable iron. Said composition is preferable formulated for oral delivery, such as a dried powder, and used in a method of treating a viral infection such as coronavirus or SARS-CoV-2 infection.
9.WO/2023/010088NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-COV-2 SPIKE PROTEINS, AND MRNA VACCINE SPIKE PROTEINS
WO - 02.02.2023
Int.Class A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
 Appl.No PCT/US2022/074271 Applicant PONO LIFESTYLE COLORADO, LLC Inventor FLUGA, Mark
Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.
10.WO/2023/079466TREATMENT OF SEQUELAE OF CORONAVIRUS INFECTIONS
WO - 11.05.2023
Int.Class A61K 33/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
33Medicinal preparations containing inorganic active ingredients
04Sulfur, selenium or tellurium; Compounds thereof
 Appl.No PCT/IB2022/060575 Applicant SULFAGENIX, INC. Inventor GOJON-ZORRILLA, Gabriel
The present invention features compositions and methods for treating sequelae of coronavirus infection, e.g., betacoronavirus. The present invention features a method of treating or preventing one or more sequelae of a coronavirus infection. The method includes administering to the subject a pharmaceutical composition including elemental alpha sulfur, highly polar components, and a pharmaceutically acceptable excipient in an amount and for a duration sufficient to treat or prevent the one or more sequelae of the coronavirus infection.
# -